|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013216,
umls-concept:C0162789,
umls-concept:C0178655,
umls-concept:C0205217,
umls-concept:C0332293,
umls-concept:C0442726,
umls-concept:C0681842,
umls-concept:C0684249,
umls-concept:C0995188,
umls-concept:C1274040,
umls-concept:C1414313,
umls-concept:C1511790,
umls-concept:C1516213
|
|
pubmed:issue |
20
|
|
pubmed:dateCreated |
2008-7-9
|
|
pubmed:abstractText |
Epidermal growth factor receptor (EGFR) gene copy number detected by fluorescent in situ hybridization (FISH) has proven to be useful for selection of non-small-cell lung cancer (NSCLC) patients for treatment with EGFR tyrosine kinase inhibitors. Here, we evaluate EGFR FISH as a predictive marker in NSCLC patients receiving the EGFR monoclonal antibody inhibitor cetuximab plus chemotherapy.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
10
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3351-7
|
|
pubmed:dateRevised |
2009-2-5
|
|
pubmed:meshHeading |
pubmed-meshheading:18612151-Aged,
pubmed-meshheading:18612151-Analysis of Variance,
pubmed-meshheading:18612151-Antibodies, Monoclonal,
pubmed-meshheading:18612151-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18612151-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:18612151-Female,
pubmed-meshheading:18612151-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:18612151-Genes, erbB-1,
pubmed-meshheading:18612151-Humans,
pubmed-meshheading:18612151-In Situ Hybridization,
pubmed-meshheading:18612151-In Situ Hybridization, Fluorescence,
pubmed-meshheading:18612151-Lung Neoplasms,
pubmed-meshheading:18612151-Male,
pubmed-meshheading:18612151-Middle Aged,
pubmed-meshheading:18612151-Multivariate Analysis,
pubmed-meshheading:18612151-Neoplasm Staging,
pubmed-meshheading:18612151-Patient Selection,
pubmed-meshheading:18612151-Predictive Value of Tests,
pubmed-meshheading:18612151-Prognosis,
pubmed-meshheading:18612151-Proportional Hazards Models,
pubmed-meshheading:18612151-Reference Values,
pubmed-meshheading:18612151-Risk Assessment,
pubmed-meshheading:18612151-Survival Analysis,
pubmed-meshheading:18612151-Treatment Outcome,
pubmed-meshheading:18612151-Tumor Markers, Biological
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.
|
|
pubmed:affiliation |
Southwest Oncology Group, San Antonio, USA. Fred.Hirsch@UCHSC.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
